since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world’s most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai
Company profile
Ticker
EVAX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
EVAX stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
18 Jun 24
6-K
Current report (foreign)
17 Jun 24
6-K
Current report (foreign)
7 Jun 24
6-K
Current report (foreign)
3 Jun 24
6-K
Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024
3 Jun 24
6-K
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 May 24
6-K
Current report (foreign)
24 May 24
6-K
Current report (foreign)
23 May 24
6-K
Evaxion Receives Nasdaq Notification
10 May 24
F-1
Registration statement (foreign)
6 May 24
Latest ownership filings
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
2.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 106.70 mm |
Total shares | 122.71 k |
Total puts | 0.00 |
Total calls | 11.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AE Wealth Management | 48.63 k | $40.51 mm |
Susquehanna International | 32.77 k | $28.19 mm |
Two Sigma Securities | 15.19 k | $12.65 mm |
JPM JPMorgan Chase & Co. | 9.28 k | $7.98 mm |
Beacon Capital Management | 6.88 k | $9.01 mm |
UBS UBS Group AG - Registered Shares | 4.01 k | $3.34 mm |
MS Morgan Stanley | 3.45 k | $2.87 mm |
Rhumbline Advisers | 2.11 k | $1.81 mm |
Group One Trading | 386.00 | $332.00 k |
Proequities | 0.00 | $0.00 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
18 Jun 24
12 Health Care Stocks Moving In Monday's Intraday Session
17 Jun 24
HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
4 Jun 24
Evaxion Presents Validating Immune Data From Ongoing Phase 2 Trial With AI-Designed EVX-01 Vaccine At The ASCO Annual Meeting 2024
3 Jun 24
Evaxion Biotech Q1 EPS $0.03 Beats $(0.56) Estimate, Sales $51.00K Beat $37.00K Estimate
28 May 24
Press releases
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
17 Jun 24
Evaxion Announces Business Update and First Quarter 2024 Financial Results
28 May 24
Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024
23 May 24
Evaxion Receives Nasdaq Notification
10 May 24
Sidoti Events, LLC's Virtual May Micro-Cap Conference
7 May 24